Avalo Therapeutics sets up $200 million at-the-market stock sale with Jefferies
The company ended its TD Cowen sales agreement the same day it signed a new ATM facility with Jefferies for up to $200 million in shares.
SEC filing
4 stories
The company ended its TD Cowen sales agreement the same day it signed a new ATM facility with Jefferies for up to $200 million in shares.
SEC filing
The prospectus supplement, dated November 5, 2026, lets Avalo sell shares through Jefferies over time to fund development of its lead HS drug candidate.
SEC filing
Avalo said it expects FDA feedback by year-end 2026 and plans to begin a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in the first half of 2027.
SEC filing
The neuromedicines company said Miller starts as CFO effective September 2, 2026, ahead of pivotal NOVA-2 trial results for LB-102 in schizophrenia.
SEC filing